Background: A full consensus has not been reached about the hemodynamic efficacy of hydrocortisone administration in hypotensive and vasopressor-dependent preterm neonates.
Introduction
Preterm infants, especially very low birth weight infants (birth weight <1500 g), account for a significant percentage of all neonatal mortality. 1 Although a causal relationship has yet to be established, one variable associated with increased mortality in the preterm infant is systemic hypotension. In addition to increased mortality, systemic hypotension has also been associated with other adverse events, such as intraventricular hemorrhage, periventricular leukomalacia, and neurodevelopmental morbidity. 2 -5 Although the normal gestational and postnatal age-dependent blood pressure range is not known, systemic hypotension is commonly defined in one of two ways in clinical research examining this patient population. According to the more frequently used definition of systemic hypotension in clinical research, a neonate is considered as hypotensive if his/her mean blood pressure is below the fifth or tenth percentile of the normative data for the infant's gestational and postnatal age and weight. 6 The less frequently used definition of hypotension is a mean blood pressure less than or equal in numbers to the patient's gestational age in weeks. This definition is mostly used for the first postnatal day(s) and more so in clinical practice than in research studies.
The standard empiric treatment for systemic hypotension includes the use of volume expanders, vasopressor/inotropes (for example dopamine, epinephrine), and/or inotropes (for example dobutamine). 7, 8 However, a significant proportion of preterm infants do not respond to these treatments and presents with ongoing hypotension or become dependent on vasopressor/inotrope administration to maintain blood pressure at the perceived minimally acceptable levels. 7, 9 The etiology of the ongoing hypotension and vasopressor dependence is thought to be due, at least in part, to the relative adrenal insufficiency of the preterm infant. 9, 10 In addition, downregulation of the cardiovascular adrenergic receptors because of chronic stimulation and critical illness has also been implicated as a cause of ongoing hypotension and vasopressor dependence. 11, 12 As one of the genomic actions of corticosteroids is the upregulation of cardiovascular adrenergic receptor expression, receptor downregulation is thought to be enhanced in patients with relative adrenal insufficiency. 10, 12, 13 Therefore, the use of corticosteroids to treat vasopressor-resistant hypotension addresses both the relative adrenal insufficiency and receptor downregulation.
Hydrocortisone is the corticosteroid most frequently used for the treatment of vasopressor-resistant hypotension in the preterm neonate in the clinical practice because of its perceived effectiveness and lack of evidence for neurodevelopmental side effects. Although hydrocortisone has been shown to increase blood pressure and reduce vasopressor dependence in preterm infants, 9,13-18 the sample sizes used in studies examining these relationships have been relatively small, limiting the certainty and generalizability of results.
The purpose of this study is to provide a quantitative review of research examining the relationship between hydrocortisone administration, hypotension, and vasopressor requirements through the use of meta-analytic techniques.
We tested the following three specific hypotheses:
1. Hydrocortisone administration will significantly increase blood pressure in hypotensive preterm infants. 2. Hydrocortisone administration will significantly increase blood pressure in vasopressor-dependent preterm infants. 3. Among preterm infants with vasopressor-dependent hypotension, hydrocortisone administration will significantly reduce the dose of vasopressors required to maintain blood pressure in the perceived normal range.
Methods

Data sources
Ovid Medline, EBM-Cochrane Database of Systematic Reviews, EBM-Cochrane Central Register of Controlled Trials, and EBM-Database of Abstracts of Reviews of Effects were used to search for all studies examining hydrocortisone administration for the treatment of hypotension in preterm infants. Ancestry search techniques were used to further identify studies.
Study selection
To be included in the meta-analysis, studies must have examined hydrocortisone therapy for treatment of hypotension in preterm infants and contain sufficient information to calculate an effect size correlation. To address hypothesis # 1, all studies examining hydrocortisone therapy for the treatment of hypotension in preterm infants were meta-analytically examined. To address hypotheses # 2 and # 3, all studies in which hydrocortisone was administered to preterm infants with vasopressor-dependent hypotension were meta-analytically examined. Inclusion of studies did not depend on the type of the study, and thus retrospective, prospective observational, and randomized placebo-controlled clinical trials were all included. The main meta-analysis included only studies from peer-reviewed journals. An additional meta-analysis was performed, which included abstracts from professional conferences.
Studies examining prophylactic hydrocortisone therapy were not included in the meta-analysis.
Data extraction
Standard meta-analytic techniques were used to calculate and combine the effect sizes from each study included in the metaanalysis. 19 .
The Pearson correlation coefficient r was used as the effect size indicator. Although effect size indicators such as the odds ratio, risk difference, and relative risk are more commonly used in biomedical research than the Pearson correlation coefficient, there are several problematic issues inherent to their use. The odds ratio, risk difference, and relative risk provide an inconsistent measure of effect size and are less useful than the Pearson correlation coefficient for meta-analytic procedures. A complete discussion of the issues inherent to the use of the odds ratio, risk difference, and relative risk is beyond the scope of this paper, and we refer the reader to other sources for a discussion. 19, 20 Effect sizes were directly calculated from descriptive data presented by studies whenever possible. In the event that descriptive data were not presented, effect size estimates were obtained from test statistics or associated significance levels. A conservative approach was taken with studies which did not present descriptive data or test statistics and reported significance tests as 'not statistically significant' without providing a significance level. These studies were assigned a significance level of p one-tail ¼ 0.50, with an associated effect size r ¼ 0.00.
Retrievability bias has been discussed as a potential source of bias in meta-analytic research. After the basic principles of statistical significance testing, published research and abstracts from professional conferences may represent the 5% of studies that obtained significant results because of Type I error.
One statistical method of addressing this concern is to calculate the number of studies with null results (p ¼ 0.50) that would have to be added to the meta-analysis to bring the results of the metaanalysis to a non-significant level (typically defined as p ¼ 0.05). 19 This is referred to as the Failsafe N. Thus, the Failsafe N (symbolized by the letter 'k') is then interpreted as the number of studies with null results required to refute the conclusions of a meta-analysis. These studies may be the ones that failed to reach publication status and/or potential future studies that might yield null results.
If a large number of studies are required to refute the conclusions of the meta-analysis, the conclusions of the metaanalysis are interpreted as having a large tolerance for unpublished null results or future studies that may yield null results.
Results
To examine hypothesis # 1, seven published studies (N ¼ 144) investigating the effect of hydrocortisone on hypotension 9, [13] [14] [15] [16] [17] [18] Hydrocortisone for hypotension in preterms: a meta-analysis S Higgins et al were identified and included in the primary meta-analysis. Four abstracts [21] [22] [23] [24] from professional conferences examining the effect of hydrocortisone on blood pressure (N ¼ 77) were identified and included in the secondary meta-analysis.
To examine hypotheses # 2 and # 3, five published studies (N ¼ 93) investigating the effect of hydrocortisone on hypotension and vasopressor requirements in vasopressordependent hypotensive preterm infants were identified and included in the primary meta-analysis. 9, 13, [16] [17] [18] Four abstracts [21] [22] [23] [24] from professional conferences examining the effect of hydrocortisone on hypotension and vasopressor requirements in vasopressor-dependent preterm infants (N ¼ 74) were identified and included in the secondary meta-analysis. Study sample sizes and associated effect size estimates for blood pressure increases and reductions in vasopressor requirements are presented in the Table 1 . Greater values of the effect size estimate 'r' indicate greater increases in blood pressure and ability to reduce vasopressor administration.
Dosage strategy used in each study is presented in Table 1 . Owing to the extremely small number of studies in which the cumulative amount of hydrocortisone could be determined, dosage strategy was not included as a moderator variable in the meta-analysis.
Random effects meta-analysis Primary meta-analysis Hypothesis # 1. Random effects meta-analysis, in which individual studies are considered the sampling unit, found hydrocortisone therapy to significantly increase blood pressure in the hypotensive preterm neonate (r ¼ 0.71, 95%CI ¼ 0.18 to 0.92).
Hypotheses
# 2 and # 3. Among studies examining preterm neonates with vasopressor-resistant hypotension, hydrocortisone therapy significantly increased blood pressure (r ¼ 0.71 95%CI ¼ À0.19 to 0.96) and reduced vasopressor requirements (r ¼ 0.74, 95%CI ¼ 0.0084 to 0.96). Secondary meta-analysis (inclusion of abstracts from professional conferences) Hypothesis # 1. After inclusion of abstracts from professional conferences, hydrocortisone therapy was again found to significantly increase blood pressure (r ¼ 0.83, 95%CI ¼ 0.30 to 0.
95).
Hypotheses # 2 and # 3. Among studies examining preterm neonates with vasopressor-resistant hypotension, inclusion of abstracts from professional conferences found hydrocortisone For blood pressure increase and vasopressor requirement reduction among preterm neonates with vasopressor-resistant hypotension, the number of new, or unretrieved, studies averaging null results required to bring the overall p to 0.05 were k ¼ 27 and 47, respectively.
Secondary meta-analysis (inclusion of abstracts from professional conferences) Hypothesis # 1. After inclusion of abstracts from professional conferences, hydrocortisone therapy was again found to significantly increase blood pressure (r ¼ 0.65, 95%CI ¼ 0.56 to 0.72).
After inclusion of abstracts from professional conferences, Failsafe N analysis found the number of new, or unretrieved, studies averaging null results required to bring the overall p to 0.05 to be k ¼ 201 for blood pressure increase.
Hypotheses # 2 and # 3. Among preterm neonates with vasopressor-dependent hypotension, hydrocortisone therapy was again found to significantly increase blood pressure (r ¼ 0.64, 95%CI ¼ 0.55 to 0.72) and decrease vasopressor requirements (r ¼ 0.742 95%CI ¼ 0.78 to 0.81) after inclusion of abstracts from professional conferences.
For blood pressure increase and vasopressor requirement reduction among preterm neonates with vasopressor-resistant hypotension, inclusion of abstracts from professional conferences increased the number of new, or unretrieved, studies averaging null results required to bring the overall p to 0.05 to be k ¼ 74 and 188, respectively.
Discussion
The results of this meta-analysis support hypothesis # 1, finding that hydrocortisone administration significantly increases blood pressure in hypotensive preterm infants. The results of this meta-analysis also support hypotheses # 2 and # 3, finding that hydrocortisone administration significantly increases blood pressure and reduces vasopressor requirements in hypotensive and vasopressor-dependent preterm infants. Inclusion of abstracts from professional conferences provided further evidence supporting the efficacy of hydrocortisone administration in this patient population. Thus, hydrocortisone administration seems to be an effective therapy to raise blood pressure and decrease vasopressor requirements in the preterm infant with hypotension and vasopressor resistance. Indeed, the relationships found in this meta-analysis are robust, with a large tolerance for unpublished, or future, null results.
It is important to note that when calculating the effect size estimate for many of the studies included in this meta-analysis, the effect of hydrocortisone was compared with a value of no improvement in blood pressure and vasopressor reduction. Therefore, this analysis may have resulted in an overestimation of the efficacy of hydrocortisone. Indeed, increases in blood pressure among neonates from studies without a placebo-control group were much greater than the magnitude of the placebo effect found in placebo-controlled studies, and the magnitude of effect sizes calculated by this procedure was larger than the effect sizes obtained from studies which compared hydrocortisone efficacy with a placebo. Nonetheless, effect size estimates obtained from all studies were relatively large and were all statistically significant by traditional standards.
Other issues adding to the difficulty of definitive calculation of the magnitude of the efficacy of hydrocortisone therapy include multiple types of measures used by studies to determine the magnitude of the effect of hydrocortisone therapy and reporting of significance test results by studies as 'non-significant' without providing a test statistic or p-value. Use of dichotomous outcome variables (that is does hypotension resolve, yes or no) limits the amount of information available for calculation of effect size estimates. In our analysis, the studies that reported significance test results as 'non-significant' underestimate the magnitude of the effect of hydrocortisone therapy, as such results were conservatively assumed to have an effect size of zero and an associated p-value of 0.50.
Although this meta-analysis has found hydrocortisone to be an effective therapy for the treatment of preterm neonates with hypotension and vasopressor dependence, it is unknown whether the beneficial cardiovascular actions of hydrocortisone translate into improvements in clinically relevant medium-to long-term outcome measures.
Although the medium-to long-term clinical benefit of hydrocortisone therapy has yet to be established, recent data indicate hydrocortisone administration increases tissue perfusion, aiding to the prevention of ischemic tissue injury. 18 Other studies have shown that increases in blood pressure are associated with increases in cerebral blood flow in hypotensive preterm neonates. 25, 26 Thus, by increasing blood pressure, hydrocortisone therapy may attenuate or prevent cerebral injury, which has been closely associated with decreased cerebral blood flow. On the other hand, sudden uncontrolled increases in blood pressure may be harmful. Therefore, it is of utmost importance to investigate the medium-and long-term central nervous system and neurodevelopmental effects of hydrocortisone administration in hypotensive preterm neonates with vasopressor resistance.
Although short-term side effects, such as an increase in the incidence of spontaneous ileal perforations with co-exposure to indomethacin, have been documented, 27 potential long-term sequelae of hydrocortisone administration in preterm neonates have not been adequately studied. Recent findings suggest that, unlike dexamethasone, hydrocortisone may be devoid of long-term neurodevelopmental sequelae. 28 However, further investigation of the long-term effects of hydrocortisone therapy is needed before these concerns can be put to rest.
In this meta-analysis, adverse effects occurred too infrequently to permit quantitative examination. As more studies examining potential long-term sequelae become available, meta-analytic techniques may be used to quantitatively review adverse effects of hydrocortisone therapy.
Prophylactic hydrocortisone therapy was not examined in this meta-analysis. Available data suggest that prophylactic use of hydrocortisone may be beneficial in preventing hypotension in the preterm neonate. 29 As the administration of hydrocortisone in the hypotensive preterm infant seems to be an effective therapy for increasing blood pressure and decreasing vasopressor dependence, prophylactic use of hydrocortisone may decrease cardiovascular instability in the preterm neonate. However, as long as co-exposure with indomethacin is a possibility and the long-term sequelae of hydrocortisone administration have not been adequately studied, this approach cannot be recommended.
In summary, hydrocortisone administration seems to be an effective therapy for the treatment of hypotension and vasopressor dependence in the hypotensive preterm infant. Actual clinical benefits of increasing blood pressure and decreasing vasopressor requirements, however, remain unknown and further research is necessary to examine the clinical benefits of increasing blood pressure and decreasing vasopressor requirements and to determine the long-term effects of hydrocortisone therapy.
